1. Abubakar II, Tillmann T, Banerjee A. Global, regional, and national age-sex
specific all-cause and cause-specific mortality for 240 causes of death, 1990–
2013: a systematic analysis for the Global Burden of Disease Study 2013.
Lancet. 2015;385(9963):117–71.
2. Kudo M. Lenvatinib may drastically change the treatment landscape of
hepatocellular carcinoma. Liver Cancer. 2018;7(1):1–19. https://doi.org/10.11
59/000487148.
3. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus
sorafenib in first-line treatment of patients with unresectable hepatocellular
carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;
391(10126):1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1.
4. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab
plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med.
2020;382(20):1894–905. https://doi.org/10.1056/NEJMoa1915745.
5. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab
after sorafenib in patients with advanced hepatocellular carcinoma and
increased α-fetoprotein concentrations (REACH-2): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–96.
https://doi.org/10.1016/S1470-2045(18)30937-9.
6. Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, et al.
Prospective genotyping of hepatocellular carcinoma: clinical implications of
next-generation sequencing for matching patients to targeted and immune
therapies. Clin Cancer Res. 2019;25(7):2116–26. https://doi.org/10.1158/10780432.CCR-18-2293.
7. von Felden J, Craig AJ, Garcia-Lezana T, Labgaa I. Mutations in circulating
tumor DNA predict primary resistance to systemic therapies in advanced
hepatocellular carcinoma. Oncogene. 2021;40(1):140–51. https://doi.org/10.1
038/s41388-020-01519-1.
8. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al.
Whole-genome sequencing of liver cancers identifies etiological influences
on mutation patterns and recurrent mutations in chromatin regulators. Nat
Genet. 2012;44(7):760–4. https://doi.org/10.1038/ng.2291.
9. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, et al.
Identification of driver genes in hepatocellular carcinoma by exome
sequencing. Hepatology. 2013;58(5):1693–702. https://doi.org/10.1002/hep.2
6540.
10. Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S,
et al. Exome sequencing of hepatocellular carcinomas identifies new
mutational signatures and potential therapeutic targets. Nat Genet. 2015;
47(5):505–11. https://doi.org/10.1038/ng.3252.
11. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular
carcinoma using next-generation sequencing. J Hepatol. 2016;65(5):1031–42.
https://doi.org/10.1016/j.jhep.2016.05.035.
Fujii et al. Journal of Experimental & Clinical Cancer Research
(2021) 40:215
12. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor
heterogeneity and branched evolution revealed by multiregion sequencing. N Engl
J Med. 2012;366(10):883–92. https://doi.org/10.1056/NEJMoa1113205.
13. Russano M, Napolitano A, Ribelli G. Liquid biopsy and tumor heterogeneity
in metastatic solid tumors: the potentiality of blood samples. J Exp Clin
Cancer Res. 2020;39(1):95. https://doi.org/10.1186/s13046-020-01601-2.
14. Weng J, Atyah M, Zhou C, Ren N. Prospects and challenges of circulating
tumor DNA in precision medicine of hepatocellular carcinoma. Clin Exp
Med. 2020;20(3):329–37. https://doi.org/10.1007/s10238-020-00620-9.
15. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, et al. Cancer genome
scanning in plasma: detection of tumor-associated copy number
aberrations, single-nucleotide variants, and tumoral heterogeneity by
massively parallel sequencing. Clin Chem. 2013;59(1):211–24. https://doi.
org/10.1373/clinchem.2012.196014.
16. Liao H, Li H. Advances in the detection technologies and clinical
applications of circulating tumor DNA in metastatic breast Cancer. Cancer
Manag Res. 2020;12:3547–60. https://doi.org/10.2147/CMAR.S249041.
17. Wei J, Liu X, Li T, Xing P, Zhang C, Yang J. The new horizon of liquid biopsy
in sarcoma: the potential utility of circulating tumor nucleic acids. J Cancer.
2020;11(18):5293–308. https://doi.org/10.7150/jca.42816.
18. Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, et al.
Circulating tumor DNA analysis for liver cancers and its usefulness as a
liquid biopsy. Cell Mol Gastroenterol Hepatol. 2015;1(5):516–34. https://doi.
org/10.1016/j.jcmgh.2015.06.009.
19. Yamauchi M, Urabe Y, Ono A, Miki D, Ochi H, Chayama K. Serial profiling of
circulating tumor DNA for optimization of anti-VEGF chemotherapy in
metastatic colorectal cancer patients. Int J Cancer. 2018;142(7):1418–26.
https://doi.org/10.1002/ijc.31154.
20. He G, Chen Y, Zhu C, Zhou J, Xie X, Fei R, et al. Application of plasma
circulating cell-free DNA detection to the molecular diagnosis of
hepatocellular carcinoma. Am J Transl Res. 2019;11(3):1428–45.
21. Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, et al. Detecting
circulating tumor DNA in hepatocellular carcinoma patients using droplet
digital PCR is feasible and reflects Intratumoral heterogeneity. J Cancer.
2016;7(13):1907–14. https://doi.org/10.7150/jca.15823.
22. Ikeda S, Lim JS, Kurzrock R. Analysis of tissue and circulating tumor DNA by
next-generation sequencing of hepatocellular carcinoma: implications for
targeted therapeutics. Mol Cancer Ther. 2018;17(5):1114–22. https://doi.org/1
0.1158/1535-7163.MCT-17-0604.
23. Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, et al. Nextgeneration sequencing of circulating tumor DNA reveals frequent
alterations in advanced hepatocellular carcinoma. Oncologist. 2018;23(5):
586–93. https://doi.org/10.1634/theoncologist.2017-0479.
24. Howell J, Atkinson SR, Pinato DJ, Knapp S, Ward C, Minisini R, et al.
Identification of mutations in circulating cell-free tumour DNA as a
biomarker in hepatocellular carcinoma. Eur J Cancer. 2019;116:56–66.
https://doi.org/10.1016/j.ejca.2019.04.014.
25. Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, et al. Early
assessment of lung Cancer immunotherapy response via circulating tumor
DNA. Clin Cancer Res. 2018;24(8):1872–80. https://doi.org/10.1158/10780432.CCR-17-1341.
26. O'Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, et al. Early
circulating tumor DNA dynamics and clonal selection with palbociclib and
fulvestrant for breast cancer. Nat Commun. 2018;9(1):896. https://doi.org/1
0.1038/s41467-018-03215-x.
27. Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, et al. Early
reduction in ctDNA predicts survival in patients with lung and bladder
Cancer treated with Durvalumab. Clin Cancer Res. 2018;24(24):6212–22.
https://doi.org/10.1158/1078-0432.CCR-18-0386.
28. World Medical Association Declaration of Helsinki. Ethical principles for
medical research involving human subjects. JAMA. 2013;310(20):2191–4.
29. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for
hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. https://doi.
org/10.1055/s-0030-1247132.
30. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.
New response evaluation criteria in solid tumours: revised RECIST guideline
(version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2
008.10.026.
31. Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al.
Analytical and clinical validation of a digital sequencing panel for
quantitative, highly accurate evaluation of cell-free circulating tumor DNA.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
Page 17 of 18
PLoS One. 2015;10(10):e0140712. https://doi.org/10.1371/journal.pone.014
0712.
Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, et al.
The landscape of actionable genomic alterations in cell-free circulating
tumor DNA from 21,807 advanced Cancer patients. Clin Cancer Res. 2018;
24(15):3528–38. https://doi.org/10.1158/1078-0432.CCR-17-3837.
Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, et al.
Validation of a plasma-based comprehensive Cancer genotyping assay
utilizing orthogonal tissue- and plasma-based methodologies. Clin Cancer
Res. 2018;24(15):3539–49. https://doi.org/10.1158/1078-0432.CCR-17-3831.
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB:
A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017;1:1–6 PO.17.
00011.
Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al.
ClinVar: public archive of relationships among sequence variation and
human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980–5.
https://doi.org/10.1093/nar/gkt1113.
Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC:
the catalogue of somatic mutations in Cancer. Nucleic Acids Res. 2019;
47(D1):D941–d7. https://doi.org/10.1093/nar/gky1015.
Li Q, Wang K. InterVar: clinical interpretation of genetic variants by the 2015
ACMG-AMP guidelines. Am J Hum Genet. 2017;100(2):267–80. https://doi.
org/10.1016/j.ajhg.2017.01.004.
Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, et al.
CIViC is a community knowledgebase for expert crowdsourcing the clinical
interpretation of variants in cancer. Nat Genet. 2017;49(2):170–4. https://doi.
org/10.1038/ng.3774.
Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira
A, et al. Cancer genome interpreter annotates the biological and clinical
relevance of tumor alterations. Genome Med. 2018;10(1):25. https://doi.org/1
0.1186/s13073-018-0531-8.
Wang J, Huang A, Wang YP, Yin Y, Fu PY, Zhang X, et al. Circulating tumor
DNA correlates with microvascular invasion and predicts tumor recurrence
of hepatocellular carcinoma. Ann Transl Med. 2020;8(5):237. https://doi.org/1
0.21037/atm.2019.12.154.
Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. Utility of liquid biopsy analysis
in detection of hepatocellular carcinoma, determination of prognosis, and
disease monitoring: a systematic review. Clin Gastroenterol Hepatol. 2020;
18(13):2879–2902.e9.
Cai J, Chen L. Genome-wide mapping of 5-hydroxymethylcytosines in
circulating cell-free DNA as a non-invasive approach for early detection of
hepatocellular carcinoma. Gut. 2019;68(12):2195–205. https://doi.org/10.113
6/gutjnl-2019-318882.
An Y, Guan Y, Xu Y, Han Y, Wu C, Bao C, et al. The diagnostic and
prognostic usage of circulating tumor DNA in operable hepatocellular
carcinoma. Am J Transl Res. 2019;11(10):6462–74.
Long G, Fang T, Su W, Mi X, Zhou L. The prognostic value of postoperative
circulating cell-free DNA in operable hepatocellular carcinoma. Scand J
Gastroenterol. 2020;55(12):1441–6. https://doi.org/10.1080/00365521.2020.1
839127.
Bulbul A, Leal A, Husain H. Applications of cell-free circulating tumor DNA
detection in EGFR mutant lung cancer. J Thorac Dis. 2020;12(5):2877–82.
https://doi.org/10.21037/jtd.2020.01.66.
Klein-Scory S, Wahner I, Maslova M, Al-Sewaidi Y, Pohl M, Mika T, et al.
Evolution of RAS mutational status in liquid biopsies during first-line
chemotherapy for metastatic colorectal Cancer. Front Oncol. 2020;10:1115.
https://doi.org/10.3389/fonc.2020.01115.
van Helden EJ, Angus L. RAS and BRAF mutations in cell-free DNA are
predictive for outcome of cetuximab monotherapy in patients with tissuetested RAS wild-type advanced colorectal cancer. Mol Oncol. 2019;13(11):
2361–74. https://doi.org/10.1002/1878-0261.12550.
Yamada T, Matsuda A, Takahashi G, Iwai T, Takeda K, Ueda K, et al. Emerging
RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal
patients are associated with both primary and secondary resistance to firstline anti-EGFR therapy. Int J Clin Oncol. 2020;25(8):1523–32. https://doi.org/1
0.1007/s10147-020-01691-0.
Oh CR, Kong SY, Im HS, Kim HJ, Kim MK, Yoon KA, et al. Genome-wide copy
number alteration and VEGFA amplification of circulating cell-free DNA as a
biomarker in advanced hepatocellular carcinoma patients treated with
Sorafenib. BMC Cancer. 2019;19(1):292. https://doi.org/10.1186/s12885-0195483-x.
Fujii et al. Journal of Experimental & Clinical Cancer Research
(2021) 40:215
50. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour
evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4.
https://doi.org/10.1038/nature09807.
51. Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, et al. Prognostic and predictive
impact of circulating tumor DNA in patients with advanced cancers treated
with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842–53.
https://doi.org/10.1158/2159-8290.CD-20-0047.
52. Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFPnegative hepatocellular carcinoma. Front Oncol. 2020;10:1316. https://doi.
org/10.3389/fonc.2020.01316.
53. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for
detecting hepatocellular carcinoma in patients with hepatitis C. a systematic
review and critical analysis. Ann Intern Med. 2003;139(1):46–50. https://doi.
org/10.7326/0003-4819-139-1-200307010-00012.
54. Kodama K, Kawaoka T, Namba M, Uchikawa S, Ohya K, Morio K, et al.
Correlation between early tumor marker response and imaging response in
patients with advanced hepatocellular carcinoma treated with Lenvatinib.
Oncology. 2019;97(2):75–81. https://doi.org/10.1159/000499715.
55. Nance T, Helman E, Artieri C, Yen J, Slavin TP, Chudova D, et al. Abstract
4272: A novel approach to differentiation of somatic vs. germline variants in
liquid biopsies using a betabinomial model. Cancer Res. 2018;78(13
Supplement):4272.
56. Nakamura Y, Taniguchi H. Clinical utility of circulating tumor DNA
sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN
and GOZILA studies. Nat Med. 2020;26(12):1859–64. https://doi.org/10.1038/
s41591-020-1063-5.
57. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, et al.
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.
Nat Genet. 2014;46(12):1267–73. https://doi.org/10.1038/ng.3126.
58. Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J. Clinical impact
of genomic diversity from early to advanced hepatocellular carcinoma.
Hepatology. 2020;71(1):164–82. https://doi.org/10.1002/hep.30811.
59. Brunner SF, Roberts ND, Wylie LA, Moore L, Aitken SJ, Davies SE, et al.
Somatic mutations and clonal dynamics in healthy and cirrhotic human
liver. Nature. 2019;574(7779):538–42. https://doi.org/10.1038/s41586-019-1
670-9.
60. Lombardo D, Saitta C, Giosa D, Di Tocco FC, Musolino C, Caminiti G, et al.
Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1
genes in patients with hepatocellular carcinoma from southern Italy. Oncol
Lett. 2020;19(3):2368–74. https://doi.org/10.3892/ol.2020.11332.
61. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High
frequency of telomerase reverse-transcriptase promoter somatic mutations
in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;
4(1):2218. https://doi.org/10.1038/ncomms3218.
62. Amirouchene-Angelozzi N, Swanton C, Bardelli A. Tumor evolution as a
therapeutic target. Cancer Discov. 2017;7(8):805–17. https://doi.org/10.11
58/2159-8290.CD-17-0343.
63. Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, et al. A blood-based assay
for assessment of tumor mutational burden in first-line metastatic NSCLC
treatment: results from the MYSTIC study. Clin Cancer Res. 2021;27(6):1631–
40. https://doi.org/10.1158/1078-0432.CCR-20-3771.
64. Carausu M, Melaabi S. ESR1 mutation detection and dynamics in meningeal
Carcinomatosis in breast Cancer. J Breast Cancer. 2020;23(2):218–23. https://
doi.org/10.4048/jbc.2020.23.e4.
65. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1
mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;
45(12):1446–51. https://doi.org/10.1038/ng.2823.
66. Ongusaha PP, Kim JI, Fang L, Wong TW, Yancopoulos GD, Aaronson SA,
et al. p53 induction and activation of DDR1 kinase counteract p53-mediated
apoptosis and influence p53 regulation through a positive feedback loop.
EMBO J. 2003;22(6):1289–301. https://doi.org/10.1093/emboj/cdg129.
67. Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, et al.
Combined inhibition of DDR1 and notch signaling is a therapeutic strategy
for KRAS-driven lung adenocarcinoma. Nat Med. 2016;22(3):270–7. https://
doi.org/10.1038/nm.4041.
68. Ambrogio C, Nadal E, Villanueva A, Gómez-López G, Cash TP, Barbacid M,
et al. KRAS-driven lung adenocarcinoma: combined DDR1/notch inhibition
as an effective therapy. ESMO Open. 2016;1(5):e000076. https://doi.org/1
0.1136/esmoopen-2016-000076.
69. Das S, Ongusaha PP, Yang YS, Park JM, Aaronson SA, Lee SW. Discoidin
domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
Page 18 of 18
promotes chemoresistance through nuclear factor-kappaB pathway
activation. Cancer Res. 2006;66(16):8123–30. https://doi.org/10.1158/0008-54
72.CAN-06-1215.
Henriet E, Sala M, Abou Hammoud A, Tuariihionoa A, Di Martino J, Ros M,
et al. Multitasking discoidin domain receptors are involved in several and
specific hallmarks of cancer. Cell Adhes Migr. 2018;12(4):363–77. https://doi.
org/10.1080/19336918.2018.1465156.
Choi M, Kipps T, Kurzrock R. ATM mutations in Cancer: therapeutic
implications. Mol Cancer Ther. 2016;15(8):1781–91. https://doi.org/10.1158/1
535-7163.MCT-15-0945.
Beggs AD, Domingo E, McGregor M, Presz M, Johnstone E, Midgley R, et al.
Loss of expression of the double strand break repair protein ATM is
associated with worse prognosis in colorectal cancer and loss of Ku70
expression is associated with CIN. Oncotarget. 2012;3(11):1348–55. https://
doi.org/10.18632/oncotarget.694.
Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R, et al. Functional
analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the
level of p21 is associated with short response duration. Clin Cancer Res.
2012;18(15):4191–200. https://doi.org/10.1158/1078-0432.CCR-11-2936.
Fujimaki S, Matsuda Y, Wakai T, Sanpei A, Kubota M, Takamura M, et al.
Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to
sorafenib by interfering with Akt signaling. Cancer Lett. 2012;319(1):98–108.
https://doi.org/10.1016/j.canlet.2011.12.043.
Liu J, Liu Y, Meng L, Ji B, Yang D. Synergistic antitumor effect of Sorafenib
in combination with ATM inhibitor in hepatocellular carcinoma cells. Int J
Med Sci. 2017;14(6):523–9. https://doi.org/10.7150/ijms.19033.
Jeric I, Maurer G, Cavallo AL, Raguz J, Desideri E, Tarkowski B, et al. A cellautonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. Nat
Commun. 2016;7(1):13781. https://doi.org/10.1038/ncomms13781.
Ghousein A, Mosca N, Cartier F, Charpentier J, Dupuy JW, Raymond AA.
miR-4510 blocks hepatocellular carcinoma development through RAF1
targeting and RAS/RAF/MEK/ERK signalling inactivation. Liver Int. 2020;40(1):
240–51. https://doi.org/10.1111/liv.14276.
Tian N, Wu D, Tang M, Sun H, Ji Y, Huang C, et al. RAF1 expression is
correlated with HAF, a parameter of liver computed tomographic perfusion,
and may predict the early therapeutic response to Sorafenib in advanced
hepatocellular carcinoma patients. Open Med. 2020;15(1):167–74. https://doi.
org/10.1515/med-2020-0024.
Jeong WJ, Yoon J, Park JC, Lee SH, Lee SH, Kaduwal S, et al. Ras stabilization
through aberrant activation of Wnt/β-catenin signaling promotes intestinal
tumorigenesis. Sci Signal. 2012;5(219):ra30.
Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG,
et al. Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by
inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal.
2012;5(206):ra3.
Hu ZQ, Xin HY, Luo CB, Li J, Zhou ZJ, Zou JX, et al. Associations among the
mutational landscape, immune microenvironment, and prognosis in
Chinese patients with hepatocellular carcinoma. Cancer Immunol
Immunother. 2021;70(2):377–89. https://doi.org/10.1007/s00262-020-02685-7.
Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C. Castro de
Moura M, et al. identification of an immune-specific class of hepatocellular
carcinoma, based on molecular features. Gastroenterology. 2017;153(3):812–
26. https://doi.org/10.1053/j.gastro.2017.06.007.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
...
論文の公開元へ
